Relmada Therapeutics, Inc. (RLMD) Starts Presentation at LD Micro Conference

Relmada Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, is engaged in developing new versions of proven drug products along with new chemical entities that could address unmet medical need in areas of pain treatment. Guided by the internationally-recognized scientific expertise of its research team, the company’s product development efforts have yielded four lead products in various stages of development, including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. For more information, visit the company’s website at www.relmada.com.